Trials / Active Not Recruiting
Active Not RecruitingNCT04084249
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer - Intervention Trial 2
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 359 (actual)
- Sponsor
- Claus Lindbjerg Andersen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments could result in earlier detection of recurrent disease and identify more patients eligible for curative treatment.
Conditions
- Colorectal Cancer
- Colo-rectal Cancer
- ctDNA
- Gastro-Intestinal Disorder
- Colorectal Neoplasms
- Gastrointestinal Cancer
- Gastrointestinal Neoplasms
- Digestive System Disease
- Digestive System Neoplasm
- Colonic Diseases
- Colonic Neoplasms
- Colonic Cancer
- Rectal Diseases
- Rectal Neoplasms
- Rectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | ctDNA-analysis | Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA). |
| OTHER | Intensified Follow-up Schedule | PET/CT-scans every 3. month |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
- First posted
- 2019-09-10
- Last updated
- 2024-07-09
Locations
10 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT04084249. Inclusion in this directory is not an endorsement.